No Further Trials Needed to Determine if Omega-3 Fats Reduce the Risk of Cardiovascular Disease and Death

This new meta-analysis indicates that ‘no further trials are needed to better evaluate the efficacy of PUFAs in preventing death related to CVD”. A total of 100,609 patients were analyzed. Reduction in mortality due to cardiovascular issues was statistically significant with a relative risk of 0.937, CI 0.88-0.98, P=0.018. Is it time to put this decades-long debate to bed? We think so.

Pathogenic Mechanisms of Lp(a)

The Lp(a) Conundrum

Lp(a): What do with DO with it? It’s an unequivocal CV risk marker, and its pathogenic mechanisms are multiple and far-reaching. Yet it’s notoriously refractory to treatment – pharma and FxMed. Get the low-down in this month’s blog: The Lp(a) Conundrum. As you will read in the blog opener, figuring out this conundrum is near and dear to my heart. Shout out to Ann Sims, RD, LD, CDE, CLS for support writing and providing references. Ann also suggested I podcast on NFFM with lipidologist Dr. Thomas Dayspring- we’re coordinating that as I type, so stay tuned. I’d love to hear from you on this one: how are you approaching Lp(a) in practice? Thank you! ~DrKF